Logo image of 4AB.DE

ABBVIE INC (4AB.DE) Stock Price, Quote, News and Overview

FRA:4AB - Deutsche Boerse Ag - US00287Y1091 - Common Stock - Currency: EUR

161.2  +1 (+0.62%)

4AB.DE Quote, Performance and Key Statistics

ABBVIE INC

FRA:4AB (5/23/2025, 7:00:00 PM)

161.2

+1 (+0.62%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High204.45
52 Week Low141.98
Market Cap284.74B
Shares1.77B
Float1.76B
Yearly Dividend5.53
Dividend Yield3.59%
PE17.75
Fwd PE12.74
Earnings (Next)07-23 2025-07-23/bmo
IPO01-02 2013-01-02


4AB.DE short term performance overview.The bars show the price performance of 4AB.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15

4AB.DE long term performance overview.The bars show the price performance of 4AB.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 5 10 15 20 25

The current stock price of 4AB.DE is 161.2 EUR. In the past month the price increased by 1.77%. In the past year, price increased by 11.05%.

ABBVIE INC / 4AB Daily stock chart

4AB.DE Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
AMG.DE AMGEN INC 13.04 128.75B
GIS.DE GILEAD SCIENCES INC 13.71 116.78B
1GILD.MI GILEAD SCIENCES INC 13.52 115.05B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 98.47B
ARGX.BR ARGENX SE 108.79 31.42B
22UA.DE BIONTECH SE-ADR N/A 20.65B
IDP.DE BIOGEN INC 7.87 16.14B
1BIIB.MI BIOGEN INC 7.52 16.05B
1MRNA.MI MODERNA INC N/A 8.79B
0QF.DE MODERNA INC N/A 8.78B
BIO.DE BIOTEST AG 66.15 1.70B
GLPG.AS GALAPAGOS NV N/A 1.68B

About 4AB.DE

Company Profile

4AB logo image AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.

Company Info

ABBVIE INC

1 N Waukegan Rd

North Chicago ILLINOIS US

Employees: 55000

4AB Company Website

4AB Investor Relations

Phone: 18479327900

ABBVIE INC / 4AB.DE FAQ

What is the stock price of ABBVIE INC today?

The current stock price of 4AB.DE is 161.2 EUR. The price increased by 0.62% in the last trading session.


What is the ticker symbol for ABBVIE INC stock?

The exchange symbol of ABBVIE INC is 4AB and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is 4AB.DE stock listed?

4AB.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for ABBVIE INC stock?

34 analysts have analysed 4AB.DE and the average price target is 192.03 EUR. This implies a price increase of 19.12% is expected in the next year compared to the current price of 161.2. Check the ABBVIE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ABBVIE INC worth?

ABBVIE INC (4AB.DE) has a market capitalization of 284.74B EUR. This makes 4AB.DE a Mega Cap stock.


How many employees does ABBVIE INC have?

ABBVIE INC (4AB.DE) currently has 55000 employees.


What are the support and resistance levels for ABBVIE INC (4AB.DE) stock?

ABBVIE INC (4AB.DE) has a support level at 153.27 and a resistance level at 161.76. Check the full technical report for a detailed analysis of 4AB.DE support and resistance levels.


Is ABBVIE INC (4AB.DE) expected to grow?

The Revenue of ABBVIE INC (4AB.DE) is expected to grow by 6.89% in the next year. Check the estimates tab for more information on the 4AB.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ABBVIE INC (4AB.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ABBVIE INC (4AB.DE) stock pay dividends?

ABBVIE INC (4AB.DE) has a dividend yield of 3.59%. The yearly dividend amount is currently 5.53. Check the full fundamental report for a detailed analysis of 4AB.DE dividend history, reliability and sustainability.


When does ABBVIE INC (4AB.DE) report earnings?

ABBVIE INC (4AB.DE) will report earnings on 2025-07-23, before the market open.


What is the Price/Earnings (PE) ratio of ABBVIE INC (4AB.DE)?

The PE ratio for ABBVIE INC (4AB.DE) is 17.75. This is based on the reported non-GAAP earnings per share of 9.08 and the current share price of 161.2 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 4AB.DE.


4AB.DE Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to 4AB.DE. When comparing the yearly performance of all stocks, 4AB.DE is a bad performer in the overall market: 63.37% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

4AB.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE. 4AB.DE has a medium profitability rating, but doesn't score so well on its financial health evaluation.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

4AB.DE Financial Highlights

Over the last trailing twelve months 4AB.DE reported a non-GAAP Earnings per Share(EPS) of 9.08. The EPS decreased by -6.3% compared to the year before.


Industry RankSector Rank
PM (TTM) 7.24%
ROA 3.05%
ROE 292.61%
Debt/Equity 46.56
Chartmill High Growth Momentum
EPS Q2Q%6.49%
Sales Q2Q%8.39%
EPS 1Y (TTM)-6.3%
Revenue 1Y (TTM)5.45%

4AB.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to 4AB.DE. The Buy consensus is the average rating of analysts ratings from 34 analysts.

For the next year, analysts expect an EPS growth of 23.49% and a revenue growth 6.89% for 4AB.DE


Ownership
Inst Owners73.92%
Ins Owners0.07%
Short Float %N/A
Short RatioN/A
Analysts
Analysts80
Price Target192.03 (19.13%)
EPS Next Y23.49%
Revenue Next Year6.89%